TNSN00210A1 - Forme cristalline inhibitrice de nhe-1, et composition la contenant - Google Patents

Forme cristalline inhibitrice de nhe-1, et composition la contenant

Info

Publication number
TNSN00210A1
TNSN00210A1 TNTNSN00210A TNSN00210A TNSN00210A1 TN SN00210 A1 TNSN00210 A1 TN SN00210A1 TN TNSN00210 A TNTNSN00210 A TN TNSN00210A TN SN00210 A TNSN00210 A TN SN00210A TN SN00210 A1 TNSN00210 A1 TN SN00210A1
Authority
TN
Tunisia
Prior art keywords
nhe
crystalline form
composition containing
inhibitoring
containing same
Prior art date
Application number
TNTNSN00210A
Other languages
English (en)
Inventor
Joseph Connolly Terrence
Jane Li Zheng
Lee Orrill Susan
Kiritkumar Shah Bharat
Robinson Brostrom Lyle
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN00210A1 publication Critical patent/TNSN00210A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'INVENTION CONCERNE UNE FORME CRISTALLINE D'UN SEL DE FORMULE I : ELLE CONCERNE EGALEMENT UN PROCEDE POUR SA PREPARATION AINSI QU'UNE COMPOSITION PHARMACEUTIQUE LA CONTENANT. APPLICATION : UTILISATION D'UN TEL COMPOSE OU D'UNE TELLE COMPOSITION, COMME INHIBITEUR DE NHE-1, POUR REDUIRE L'ALTERATION TISSULAIRE RESULTANT D'UNE ISCHEMIE.
TNTNSN00210A 1999-10-29 2000-10-27 Forme cristalline inhibitrice de nhe-1, et composition la contenant TNSN00210A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29

Publications (1)

Publication Number Publication Date
TNSN00210A1 true TNSN00210A1 (fr) 2005-11-10

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00210A TNSN00210A1 (fr) 1999-10-29 2000-10-27 Forme cristalline inhibitrice de nhe-1, et composition la contenant

Country Status (44)

Country Link
EP (1) EP1224179B1 (fr)
JP (1) JP2003512455A (fr)
KR (1) KR100464526B1 (fr)
CN (2) CN1205205C (fr)
AP (1) AP2002002493A0 (fr)
AR (1) AR029402A1 (fr)
AT (1) ATE271047T1 (fr)
AU (1) AU778573B2 (fr)
BG (1) BG106729A (fr)
BR (1) BR0015275A (fr)
CA (1) CA2389020A1 (fr)
CO (1) CO5271714A1 (fr)
CZ (1) CZ20021332A3 (fr)
DE (1) DE60012208T2 (fr)
DK (1) DK1224179T3 (fr)
DZ (1) DZ3463A1 (fr)
EA (1) EA004937B1 (fr)
EE (1) EE200200227A (fr)
ES (1) ES2222923T3 (fr)
GE (1) GEP20043222B (fr)
GT (1) GT200000180A (fr)
HK (1) HK1048472B (fr)
HR (1) HRP20020366B1 (fr)
HU (1) HUP0204009A3 (fr)
IL (1) IL148581A0 (fr)
IS (1) IS6302A (fr)
MA (1) MA26840A1 (fr)
MX (1) MXPA02004358A (fr)
NO (1) NO20021821L (fr)
NZ (1) NZ517738A (fr)
OA (1) OA12080A (fr)
PA (1) PA8505501A1 (fr)
PE (1) PE20010764A1 (fr)
PL (1) PL354869A1 (fr)
PT (1) PT1224179E (fr)
SI (1) SI1224179T1 (fr)
SK (1) SK5312002A3 (fr)
SV (1) SV2002000209A (fr)
TN (1) TNSN00210A1 (fr)
TR (1) TR200201167T2 (fr)
UA (1) UA72002C2 (fr)
WO (1) WO2001030759A2 (fr)
YU (1) YU31502A (fr)
ZA (1) ZA200203295B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
EP1355899A1 (fr) * 2001-01-31 2003-10-29 Pfizer Products Inc. Ethanolats d'inhibiteur de type 1 d'echangeur sodium-hydrogene
MXPA04006615A (es) * 2002-01-30 2004-10-04 Pfizer Prod Inc Composiciones farmaceuticas de mesilato de zoniporida y procedimientos para mejorar la solubilidad de la zoniporida.
BR0309707A (pt) * 2002-05-02 2005-02-09 Pfizer Prod Inc Tratamento de diabetes e complicações diabéticas com inibidores nhe-1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1454902A1 (fr) * 1998-02-27 2004-09-08 Pfizer Products Inc. Dérivés de N-carbonyl-guanidine à cycle di- ou triaza-pentagonal doublement insaturé et substitué pour le traitement de l'ischémie

Also Published As

Publication number Publication date
DK1224179T3 (da) 2004-10-25
AP2002002493A0 (en) 2002-06-30
KR100464526B1 (ko) 2005-01-03
AR029402A1 (es) 2003-06-25
ATE271047T1 (de) 2004-07-15
IL148581A0 (en) 2002-09-12
UA72002C2 (en) 2005-01-17
SI1224179T1 (en) 2004-10-31
TR200201167T2 (tr) 2002-08-21
ZA200203295B (en) 2003-06-25
HK1048472B (zh) 2005-09-16
DZ3463A1 (fr) 2001-05-03
MXPA02004358A (es) 2002-11-07
OA12080A (en) 2003-08-25
CN1636991A (zh) 2005-07-13
HUP0204009A3 (en) 2004-07-28
IS6302A (is) 2002-03-15
AU7441500A (en) 2001-05-08
WO2001030759A2 (fr) 2001-05-03
HUP0204009A2 (hu) 2003-03-28
HRP20020366B1 (en) 2005-04-30
BR0015275A (pt) 2002-07-16
SV2002000209A (es) 2002-07-16
ES2222923T3 (es) 2005-02-16
PT1224179E (pt) 2004-10-29
GEP20043222B (en) 2004-04-26
EA004937B1 (ru) 2004-10-28
DE60012208T2 (de) 2005-07-21
CO5271714A1 (es) 2003-04-30
EP1224179B1 (fr) 2004-07-14
CN1384829A (zh) 2002-12-11
CA2389020A1 (fr) 2001-05-03
PL354869A1 (en) 2004-03-08
AU778573B2 (en) 2004-12-09
EE200200227A (et) 2003-06-16
MA26840A1 (fr) 2004-12-20
JP2003512455A (ja) 2003-04-02
NO20021821D0 (no) 2002-04-18
HK1048472A1 (en) 2003-04-04
EA200200416A1 (ru) 2002-10-31
BG106729A (bg) 2002-12-29
PE20010764A1 (es) 2001-07-23
HRP20020366A2 (en) 2004-02-29
CZ20021332A3 (cs) 2002-10-16
GT200000180A (es) 2002-04-11
PA8505501A1 (es) 2003-09-05
DE60012208D1 (de) 2004-08-19
SK5312002A3 (en) 2003-01-09
KR20020040918A (ko) 2002-05-30
WO2001030759A3 (fr) 2001-09-13
NO20021821L (no) 2002-04-18
CN1205205C (zh) 2005-06-08
NZ517738A (en) 2005-06-24
YU31502A (sh) 2004-12-31
EP1224179A2 (fr) 2002-07-24

Similar Documents

Publication Publication Date Title
TNSN97190A1 (fr) Derives d'amines bicycliques.
TNSN97193A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99142A1 (fr) Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation.
TNSN97070A1 (fr) Derives d'imidazole substitues, procede pour leur preparation, et compositions les contenant
PL332509A1 (en) Beta-sulphonyl-hydroxamic acids as inhibitors of intercellular substance metaloproteinases
CA2305548A1 (fr) Agonistes de la prostaglandine et leur utilisation pour le traitement des problemes osseux
TNSN00231A1 (fr) Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
CA2502856A1 (fr) Intermediaires pour les composes inhibant la protease retrovirale
TNSN99028A1 (fr) Composes nouveaux inhibiteurs de nhe-1, procede pour leur preparation et compositions pharmaceutiques les contenant
BR9909358A (pt) Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
GB0123589D0 (en) Organic compounds
TNSN00198A1 (fr) COMPOSES NOUVEAUX INHIBITEURS DE cGMP PDE, PROCEDE POUR LEUR PREPARATION ET FORMULATIONS LES CONTENANT.
IL148426A0 (en) α-HYDROXY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP1165490A4 (fr) Inhibiteurs de caspases 2-aminobenzamidiques substitues et leur utilisation
ES2194202T3 (es) Compuestos polimorfos.
AU4831899A (en) 5-HT1F agonists
TNSN00110A1 (fr) Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques le contenant
CA2341031A1 (fr) Forme de sel de pantoprazole
CA2266759A1 (fr) Derives 3-mercaptoacetylamino-1,5-substitue-2-oxo-azepane, utilises comme inhibiteurs de metalloproteinase matrice
TNSN00210A1 (fr) Forme cristalline inhibitrice de nhe-1, et composition la contenant
TNSN99002A1 (fr) Composes nouveaux inhibiteurs de mmp, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN02023A1 (fr) DERIVES DE PYRAZOLOPYRIMIDINE NOUVEAUX INHIBITEURS DE cGMP-PDE ET COMPOSITIONS LES CONTENANT.
TNSN01065A1 (fr) Inhibiteur de nhe-1, et composition le contenant
CA2455298A1 (fr) Composes polycycliques condenses